Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 12/20 | 0.45 |
| ▸ | NR1H3 | Q13133 | 11/20 | 0.45 |
| ▸ | GCK | P35557 | 2/20 | 0.43 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.41 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | RXRA | P19793 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.41 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4144286 | 0.81 | ALDH1A1 (0.49) | CHEK1FGFR1KDR | |
| SCHEMBL16576449 | 0.81 | KDR (0.59) | CHEK1FGFR1KDR | |
| SCHEMBL12907444 | 0.80 | TTK (0.54) | NR1H2NR1H3LRRK2 | |
| SCHEMBL4144767 | 0.79 | KIT (0.48) | GCKCHEK1FGFR1KDR | |
| SCHEMBL4144602 | 0.76 | KDR (0.43) | CHEK1FGFR1KDR | |
| SCHEMBL27805303 | 0.76 | KDR (0.47) | CHEK1FGFR1KDR | |
| SCHEMBL8738326 | 0.74 | HTT (0.64) | NR1H2NR1H3GCKPTGS2 | |
| SCHEMBL2448984 | 0.74 | KDR (0.45) | GCKCHEK1FGFR1KDRPTGS1 | |
| SCHEMBL16566280 | 0.73 | HTT (0.61) | NR1H2NR1H3GCKPTGS1PTGS2 | |
| SCHEMBL12907464 | 0.72 | SGK1 (0.51) | FGFR1KDRLRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090143422-A1 | P38 INHIBITORS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2009-06-04 | — | — | US | claimed |
| EP-2039685-A2 | Heterobicyclic compounds as P38 inhibitors | Array Biopharma, Inc. (US) | 2009-03-25 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143422-A1 | P38 INHIBITORS AND METHODS OF USE THEREOF | MAPKAPK2, MAPK1, MAPK8 | NR1H2 292/4885NR1H3 279/4885GCK 1901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.